Treating Pseudomonas: How Does Ceftolozane-Tazobactam Differ from Other Beta-Lactams?

Jason Pogue, PharmD, BCPS-ID, explains how ceftolozane-tazobactam differs from other beta-lactams for treating Pseudomonas infections.

Jason Pogue, PharmD, BCPS-ID, Clinical Pharmacist, Infectious Diseases, Sinai-Grace Hospital, explains how ceftolozane-tazobactam differs from other beta-lactams for treating Pseudomonas infections.

Interview Transcript (slightly modified for readability)

“What’s different about ceftolozane-tazobactam is that when you compare it to the other beta-lactams that have activity against Pseudomonas, the 3 main mechanisms of resistance that will knock out those agents, this drug is stable to. So, what’s really nice about it, and what makes it different, is that it can retain activity even in the setting of resistance [compared with] our traditional agents; it makes it a nice option from that standpoint.”

DISCLOSURES: Jason Pogue is a Consultant for Merck, Allergan, Med Co, Shionogi, Zavante, Achaogen. This study was supported by a grant from Merck.